Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 3/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.62 |
| ▸ | CNR2 | P34972 | 6/20 | 0.56 |
| ▸ | SRC | P12931 | 3/20 | 0.50 |
| ▸ | ZAP70 | P43403 | 3/20 | 0.50 |
| ▸ | SYK | P43405 | 3/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.49 |
| ▸ | ATF1 | P18846 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 3/20 | 0.46 |
| ▸ | CDK4 | P11802 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | STK16 | O75716 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3379861 | 0.89 | HDAC3 (0.54) | HDAC3HDAC1HDAC2HDAC6CNR2 | |
| SCHEMBL3379016 | 0.85 | CNR2 (0.74) | CNR2SYK | |
| SCHEMBL3382305 | 0.85 | HDAC3 (0.58) | HDAC3HDAC1HDAC2HDAC6CNR2 | |
| SCHEMBL3378695 | 0.84 | TAS2R14 (0.55) | HDAC3HDAC1HDAC2HDAC6CNR2 | |
| SCHEMBL3592990 | 0.80 | CNR2 (0.65) | HDAC3HDAC1HDAC2HDAC6CNR2 | |
| SCHEMBL3382186 | 0.79 | CNR2 (0.59) | HDAC3HDAC1HDAC2HDAC6CNR2 | |
| SCHEMBL13503375 | 0.79 | CNR2 (0.73) | CNR2CYP3A4 | |
| SCHEMBL3381215 | 0.78 | CNR2 (0.60) | HDAC3HDAC1HDAC2HDAC6CNR2 | |
| SCHEMBL3378644 | 0.77 | BRD4 (0.58) | CNR2SYK | |
| SCHEMBL8739793 | 0.77 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1878725-B1 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LTD (GB) | 2010-11-24 | — | — | EP | claimed |
| EP-1878725-B1 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LTD (GB) | 2010-11-24 | — | — | EP | disclosed |
| US-20100041654-A1 | Pyrimidine Derivatives And Their Use As CB2 Modulators | EATHERTON ANDREW JOHN | 2010-02-18 | — | — | US | disclosed |
| US-7635701-B2 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LIMITED (GB) | 2009-12-22 | — | — | US | disclosed |
| US-20080132505-A1 | Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| EP-1878725-A2 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LIMITED (GB) | 2008-01-16 | — | — | EP | disclosed |
| US-20060293354-A1 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LIMITED (GB) | 2006-12-28 | — | — | US | disclosed |
| EP-1732561-A1 | COMBINATION OF CB2 MODULATORS AND PDE4 INHIBITORS FOR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005074939-A1 | COMBINATION OF CB2 MODULATORS AND PDE4 INHIBITORS FOR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2005-08-18 | — | — | WO | disclosed |
| EP-1539712-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS CB2 MODULATORS | GLAXO GROUP LIMITED (GB) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004018433-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS CB2 MODULATORS | GLAXO GROUP LIMITED (GB) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293354-A1 | Pyrimidine derivatives and their use as CB2 modulators | CNR2, CNR1, P2RX3 | HDAC3 2645/4885HDAC1 3815/4885HDAC2 2339/4885 |
| US-20100041654-A1 | Pyrimidine Derivatives And Their Use As CB2 Modulators | CNR2, CNR1, P2RY2 | HDAC3 2919/4885HDAC1 3982/4885HDAC2 2534/4885 |
| US-20080132505-A1 | Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine | CNR2, CNR1, PDE4A | HDAC3 397/4885HDAC1 920/4885HDAC2 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.